Clinical trial · Observational
LUCID - LUng Cancer CIrculating Tumour Dna Study
NCT04153526CI-TRIAL-00041493LUCIDunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective observational pilot study to investigate levels of circulating tumour DNA (ctDNA) in plasma from patients with stage I to IIIB non-small cell lung cancer (NSCLC) who will undergo treatment with curative intent.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Procedure | — | UNRESOLVED |
| Collection or archival tumour tissue (If available) | Other | — | UNRESOLVED |
| Surplus Tumour Tissue sample collection from surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Surgical Cohort
- description
- Surgical Cohort: Patients offered surgery, with or without adjuvant chemotherapy.
- interventionNames
- Procedure: Blood sampling
- Procedure: Surplus Tumour Tissue sample collection from surgery
- Other: Collection or archival tumour tissue (If available)
- label
- Non Surgical Cohort
- description
- Non-Surgical Cohort: Stage I/II/IIIB patients undergoing radical radiotherapy (with or without chemotherapy) or stereotactic ablative radiotherapy (SABR).
- interventionNames
- Procedure: Blood sampling
- Other: Collection or archival tumour tissue (If available)
Primary outcomes (1)
- measure
- ctDNA detection rate in all patients
- timeFrame
- Baseline blood sample
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old at the time of consent * Male or Female * Patients with radiologically and histologically/cytologically confirmed stages I to IIIB NSCLC who are planning to undergo radical treatment (surgery or radical radiotherapy) with curative intent * ECOG Performance Status 0-2 * Able to give informed consent * Able to give blood Exclusion Criteria: * Unable to receive treatment with curative intent due to co-morbidity or personal choice Patients participating in other clinical studies are not precluded from entering the study; however they must meet all the eligibility criteria for this study.
References
Publications (0)
Data not yet available
No reference posted for this study.